文献速递浆细胞疾病

冒烟型多发性骨髓瘤的风险分层管理策略:从临床研究走向临床实践

Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.
PubMed 文献 · Lancet Haematol · 2022-01-01

冒烟型多发性骨髓瘤过去40余年因进展风险与治疗风险的综合考量而仅采用观察。在现代治疗时代,初治方案的疗效与毒性改善、进展风险评估工具进步,推动大量新药试验开展;两项3期试验已显示对最高危患者早期干预有显著获益,本文就此讨论并提出管理路径。

要点

  • 两项3期试验显示最高危冒烟型多发性骨髓瘤患者可从早期干预中显著获益。
  • 治疗持续时间、可接受的风险及治疗强度(治愈性 vs 预防性)仍存在不确定性,正在试验中检验。
  • 20/2/20(Mayo 2018)标准因简便和广泛可及,可能成为跨试验比较的风险分层方法。

核心结论

  • 两项3期试验已显示对最高危冒烟型多发性骨髓瘤患者早期干预有显著获益,推动风险分层管理从临床研究走向临床实践。

研究设计与样本

  • 本文为观点(Viewpoint)文章,基于两项3期试验结果及正在进行的试验,讨论冒烟型多发性骨髓瘤的风险分层管理策略。

主要发现

  • 两项3期试验显示最高危患者可从早期干预中显著获益。
  • 初治方案的疗效与毒性改善,进展风险评估工具亦进步,推动大量新药试验开展。
  • 治疗持续时间、可接受的风险及治疗强度(治愈性 vs 预防性)仍不确定,正在试验中检验。

关键数值与推荐

  • 20/2/20(Mayo 2018)标准因简便和广泛可及,可能成为跨试验比较的风险分层方法。

临床怎么用

  • 作者认为应聚焦3期试验以推动领域回答上述问题并最终改善患者结局。

局限性

  • 治疗持续时间、可接受的风险及治疗强度(治愈性 vs 预防性)仍存在不确定性,正在进行的试验中检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Smouldering multiple myeloma is a precursor condition that has been relegated to observation for more than 40 years on the basis of the pooled risk of progression relative to the risks of treatment. In the modern era of myeloma therapy, efficacy and toxicity of initial therapy have improved, as have tools for assessing risk of progression of this disease. The combination of these two advances has resulted in an explosion in the number of trials testing new drugs in patients with smouldering multiple myeloma, with the goal of preventing patients from developing the need for intensive treatment or of eliminating the malignant clone in totality. Two phase 3 trials have now shown a significant benefit of early intervention in the highest risk group of patients, leading to the discussion and approach described in this Viewpoint. Ongoing uncertainties include the duration of therapy, acceptable risks, and intensity of treatment (curative vs preventive), all of which are being tested in ongoing trials. Finally, common methods for risk stratification are crucial for allowing comparison across trials, and the 20/2/20 (Mayo 2018) criteria might be one such method, on the basis of their simplicity and broad availability. A focus on phase 3 trials is key to moving the field forward in a way that answers these questions and ultimately improves outcomes for patients.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Lonial S, Rajkumar SV, Mateos MV, et al. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. Lancet Haematol. 2022. PMID: 35114153. doi:10.1016/S2352-3026(21)00335-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。